* BioCorRx posted a net loss of **USD 1.00 million** for the quarter ended June 30, 2026, narrowing from **USD 1.38 million**. * Revenue fell **50.6%** to **USD 87,970** versus the prior-year quarter, on lower Lucemyra distribution sales. * Grant income more than doubled to **USD 679,477**, while operating expenses edged down to **USD 1.55 million**. * Cash totaled **USD 21,237** at June 30, 2026; net cash used in operating activities was **USD 873,260** for the six months ended June 30, 2026. * Working capital deficit stood at **USD 8.23 million**, with management flagging substantial doubt about going-concern over the next 12 months.
BICX•BICX•BICX•BICX•
